David Nierengarten: Zynteglo's Pricing Model Could Create 'Air Gaps' in the Company's Cash Flow - Wedbush

06/14/2019

David Nierengarten: Zynteglo’s Pricing Model Could Create ‘Air Gaps’ in the Company’s Cash Flow

For more on David Nierengarten and Jeffrey La Rosa’s comments: Bluebird prices gene therapy in Europe at $1.8M over 5 years

Recent Posts:

Recent Posts

Contact us to learn how we can partner for your financial success.